March 6, 2026 | Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, review safety considerations associated with antibody-drug conjugates such as datopotamab deruxtecan (Dato-DXd) and other emerging therapies in EGFR-mutated NSCLC. Neal discusses the management of key toxicities associated with Dato-DXd. Goldberg underscores the importance of early recognition and multidisciplinary management to minimize serious adverse outcomes while preserving clinical benefit.
Related Posts
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC
